Eli Lilly and Company (NYSE:LLY) Stock Jumps 3.6% – Time to Buy?

Eli Lilly and Company (NYSE:LLY)’s stock price shot up 3.6% during trading on Tuesday. The stock traded as high as $1,311.75 and last traded at $1,285.6060. 2,956,271 shares traded hands during mid-day trading, an increase of 0% from the average session volume of 2,947,191 shares. The stock had previously closed at $1,240.34.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Goldman Sachs raised its price target for Eli Lilly (LLY) to $1,413 from $1,371 while maintaining a Buy rating. The firm reportedly expects Lilly to beat third-quarter estimates and potentially raise guidance, citing stronger Mounjaro growth outside the U.S. and increased Zepbound volumes supported by Medicare’s GLP-1 Bridge program. Eli Lilly Gains 4.6% as Goldman Sachs Lifts Price Target to $1,413
• Positive Sentiment: Lilly’s international expansion continued with agreements covering local packaging and advanced pharmaceutical contract manufacturing in Abu Dhabi, as well as a drug-delivery collaboration with China’s Metis TechBio reportedly valued at up to $1.1 billion. These deals could support supply capacity and long-term global growth. Eli Lilly signs Abu Dhabi deal for local packaging of weight-loss medicines
• Positive Sentiment: Phase 3 SHINE-2 data showed Omvoh maintained a meaningful remission benefit in children with ulcerative colitis through one year, potentially expanding Lilly’s inflammatory bowel disease franchise if regulators approve the use. Is Pediatric Ulcerative Colitis Data Altering the Investment Case for Lilly?
• Neutral Sentiment: Second-quarter revenue increased 48% to approximately $23 billion, driven by a 60% increase in medicine volume. However, realized prices declined 13%, making continued volume growth—and Lilly’s ability to manage pricing pressure—central to the upcoming earnings outlook. Eli Lilly Grew Revenue 48% While Prices Fell
• Negative Sentiment: Novo Nordisk’s CagriSema produced encouraging weight-loss data, highlighting intensifying competition in the obesity-treatment market. While the news primarily benefits Novo and obesity-focused ETFs, it raises longer-term questions about Lilly’s market share, pricing power and valuation. Obesity ETFs to Gain as Novo’s CagriSema Shows 25% Weight Loss
• Negative Sentiment: With LLY trading near record levels and at a premium valuation, investors may be taking profits or waiting for earnings confirmation. Any slowdown in Mounjaro or Zepbound prescriptions, weaker guidance, or further price pressure could trigger a sharper pullback. How Long Can Zepbound and Mounjaro Keep Juicing Revenue Results?

Analyst Ratings Changes

Several analysts recently issued reports on LLY shares. Berenberg Bank set a $1,400.00 price target on shares of Eli Lilly and Company and gave the stock a “buy” rating in a research report on Tuesday, September 15th. JPMorgan Chase & Co. boosted their price objective on shares of Eli Lilly and Company from $1,400.00 to $1,500.00 and gave the company an “overweight” rating in a research report on Monday, September 28th. Wall Street Zen cut Eli Lilly and Company from a “buy” rating to a “hold” rating in a research note on Saturday, October 17th. TD Cowen restated a “buy” rating and set a $1,250.00 target price on shares of Eli Lilly and Company in a research note on Tuesday, September 22nd. Finally, The Goldman Sachs Group reaffirmed a “buy” rating and issued a $1,413.00 target price on shares of Eli Lilly and Company in a report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus target price of $1,317.93.

Eli Lilly and Company Price Performance

The stock has a market cap of $1.20 trillion, a P/E ratio of 42.68, a PEG ratio of 1.71 and a beta of 0.46. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00. The business’s fifty day moving average price is $1,182.84 and its 200 day moving average price is $1,116.53.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, beating analysts’ consensus estimates of $6.40 by $1.98. The company had revenue of $22.97 billion for the quarter, compared to the consensus estimate of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The firm’s quarterly revenue was up 47.7% compared to the same quarter last year. During the same period last year, the company posted $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Sell-side analysts forecast that Eli Lilly and Company will post 33.56 EPS for the current fiscal year.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the sale, the executive vice president owned 11,875 shares in the company, valued at $14,131,250. This trade represents a 29.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald Zakrowski sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the completion of the sale, the chief accounting officer owned 1,526 shares in the company, valued at $1,808,325.26. This represents a 56.72% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 13,500 shares of company stock valued at $15,958,170 in the last quarter. Insiders own 0.14% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of LLY. Ledyard National Bank boosted its stake in Eli Lilly and Company by 1.9% in the third quarter. Ledyard National Bank now owns 4,358 shares of the company’s stock worth $5,043,000 after buying an additional 82 shares in the last quarter. Virtue Asset Management LLC grew its position in Eli Lilly and Company by 2.5% during the third quarter. Virtue Asset Management LLC now owns 2,070 shares of the company’s stock valued at $2,396,000 after acquiring an additional 51 shares during the last quarter. Legacy Financial Group Inc. grew its position in Eli Lilly and Company by 34.3% during the third quarter. Legacy Financial Group Inc. now owns 356 shares of the company’s stock valued at $412,000 after acquiring an additional 91 shares during the last quarter. NBT Bank N.A. bought a new position in Eli Lilly and Company during the third quarter valued at approximately $12,664,000. Finally, Root Financial Partners LLC raised its stake in shares of Eli Lilly and Company by 19.5% during the third quarter. Root Financial Partners LLC now owns 2,146 shares of the company’s stock worth $2,484,000 after acquiring an additional 350 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.